Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.

ABSTRACT:

SUBMITTER: Goepfert PA 

PROVIDER: S-EPMC8055206 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature